ArticleScientific reports2025
Reliability, validity, and acceptability of the simplified Mandarin Chinese EORTC QLQ-OPT30 for uveal melanoma patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aimed to translate the EORTC QLQ-OPT30 into Mandarin (Simplified) Chinese and assess its reliability, validity, and acceptability among Chinese uveal melanoma (UM) patients. From January 2023 to June 2024, 60 UM patients from a tertiary hospital in central China were enrolled. The process involved both forward and back translation to develop the Mandarin (Simplified) Chinese version of the EORTC QLQ-OPT30. Statistical analyses were conducted using SPSS 25.0. Reliability was evaluated using Cronbach's α coefficient, and validity was assessed through factor analysis and Pearson correlation tests. Acceptability was determined based on response rate and average completion time. The EORTC QLQ-OPT30 module contains 26 items for all patients, with an additional 4 items for those undergoing treatments other than enucleation. The module measures various aspects such as ocular irritation, visual impairment, headaches, concerns about disease recurrence, appearance issues, functional problems related to vision impairment, reading difficulties, functional issues in the treated eye, and driving problems. The study included 60 patients (45% male, 55% female) with an average age of (55.22 ± 10.02) years. The internal consistency reliability of the multi-item scales was acceptable, with Cronbach's α values ranging from 0.848 to 0.946, except for the AP dimension, which had a lower α value of 0.567. The Mandarin (Simplified) Chinese version of the EORTC QLQ-OPT30 was tested in internal consistency, the split-half, and retest reliability, along with structural, convergent, and discriminant validity; as well as acceptability by its effectiveness, all the above demonstrated good values, making it a valuable tool for measuring health-related quality of life in Chinese UM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.